

Special Issue

Reviews on the Mechanisms of Antibiotic Action

Message from the Guest Editor

At the start of the 21st century, a rapid decline in the useful lifetime of many anti-bacterial drugs has been observed, while for some medications, such as silver, the useful lifetime is now in excess of five thousand years. Why the rather large difference? Simply a difference in the mechanisms of action. Modern anti-bacterials are, in general, highly specific desactivators of certain proteins; unfortunately, they strongly resemble natural anti-bacterials, and so bacteria are ready to deal with them, hence the low activity lifetimes. Systems such as silver have no clear targets. Action via cell wall destruction, DNA inactivation, enzyme blocking, reactive oxygen species formation, cell destruction, and combinations of all of these are proposed. This brings us to the problem of how to analyse, at the molecular level, cell activity, which requires new analytical methods. From there it will be found that even simple analyses of the constituents of cells and tissues are, in fact, sadly lacking. Hence, when suitable information finally becomes available, it should be possible to build modeling systems capable of giving correct route maps to new and novel long-lifetime antibiotics.

Guest Editor

Prof. Dr. Anthony William Coleman
LMI CNRS UMR 5615, Université Lyon 1, 69622 Villeurbanne, France

Deadline for manuscript submissions

closed (28 February 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/136113

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)